The Cancer Letter

Inside information on cancer research and drug development

In Brief

Lymphoma Research Foundation awards over $5.7M in grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Lymphoma Research Foundation awarded 29 grants, totaling more than $5.7 million, to support lymphoma research. The 2022 LRF grantee class represents 17 academic and medical institutions across North America.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

CPRIT awards $67M in research grants to Texas institutions

The governing body of the Cancer Prevention and Research Institute of Texas approved 53 grants totaling more than $67 million to state research institutions to advance the state’s fight against cancer. The grants provide funding for a wide array of cancer projects, including CPRIT Scholar recruitment awards, funding for collaborative core facilities, and support for cancer clinical trials.
Drugs & Targets

FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma

FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account